NY-UPTIME-INSTITUTE
30.7.2024 12:03:28 CEST | Business Wire | Press release
Uptime Institute today announced the release of its 14th Annual Global Data Center survey. The increased demand for digital services with both volume and compute intensity is challenging the power and cooling capabilities of much of the existing infrastructure. To meet the rising demand, data center operators and their IT clients are both investing and innovating more in their IT services and facilities and using external services. The effectiveness and impact of these investments will serve to shape the industry in the years ahead.
“Our data shows operators poised for major changes ahead on multiple levels,” said Andy Lawrence, executive director of research, Uptime Intelligence. “In 2024, we see the challenges of increased demand impacting power and cooling capabilities of existing facilities and the need for further investment to keep up with the demand. At the same time the industry needs to focus on continued staffing challenges to match capacity growth. And regulatory requirements are here and cannot be dismissed.”
Now in its 14th year, Uptime Institute’s annual survey remains the most comprehensive and longest-running study of its kind. The findings of this report highlight the practices and experiences of data center owners and operators in the areas of resiliency, sustainability, efficiency, staffing, cloud and artificial intelligence. It provides detailed insights into the digital infrastructure landscape and a view into its future trajectory. Key findings from the 2024 report include:
- Fewer than one half of data center owners and operators are tracking the metrics needed to assess their sustainability and/or meet pending regulatory requirements.
- Most operators recognize the benefits of AI and its potential. But despite many operators planning to host the technology, trust in AI for use in data center operations has declined for the third year in a row.
- The frequency and severity of data center outages remain mainly unchanged from 2023 or show small improvements. Operators are countering increases in complexity, density and extreme weather with investment and good management practices.
- Average server rack densities are increasing but remain below 8 kilowatts (kW). Most facilities do not have racks above 30kW, and those that do have only a few. This is expected to change in coming years.
- Enterprises continue to meet their IT needs with hybrid architectures. More than one half of workloads (45%) are now off-premises, continuing the gradual trend of recent years. Many continued to maintain their own data centers.
- Staffing challenges have neither improved nor worsened from 2023. More effort is needed to expand labor pools and skillsets to match the pace of capacity growth.
- Average PUE levels remain mostly flat for the fifth consecutive year, but this conceals advances in newer, larger facilities.
About the Survey:
Uptime conducted this year’s annual Global Data Center Survey online and by email in the first half of 2024. The survey participants represent a wide range of industry verticals in multiple countries. Responses were collected from a total of 879 end users registered for the survey and answered at least one question. More than one half are located in North America and Europe. Approximately one third of respondents work for professional IT/data center service providers (staff with operational or executive responsibilities for a third-party data center), such as those offering colocation, wholesale, software or cloud computing services.
Learn More:
Download the executive summary report here and register for the webinar here covering key trends and takeaways from the survey results on July 31st at 9:00 AM PDT (9:00 AM PDT, 12:00 PM EDT, and 5:00 PM BST). To join our Uptime Institute Bright Talk Channel, go to https://www.brighttalk.com/join/.
About Uptime Institute
Uptime Institute is the Global Digital Infrastructure Authority. With over 3,500 awards issued in over 118 countries around the globe, and over 1,000 currently active projects in 80+ countries, Uptime has helped tens of thousands of companies optimize critical IT assets while managing costs, resources, and efficiency.
For over 30 years, the company has established industry-leading benchmarks for data center performance, resilience, sustainability, and efficiency, which provide customers assurance that their digital infrastructure can perform across a wide array of operating conditions at a level consistent with their individual business needs. Uptime’s Tier Standard is the IT industry’s most trusted and adopted global standard for the design, construction, and operation of data centers. Offerings include the organization’s Tier Standard and Certifications, Management & Operations reviews and assessments including SCIRA-FSI financial sector risk assessment, the Sustainability Assessment and a broad range of additional risk management, performance, availability, and related offerings. Uptime Education training programs have been successfully completed by over 90,000 data center professionals, expanded by the acquisition of CNet Training, Ltd.
Uptime Institute is headquartered in New York, NY, with main offices in London, Sao Paulo, Dubai, Riyadh, Singapore, and Taipei, and full-time Uptime professionals based in over 34 countries around the world. For more information, please visit uptimeinstitute.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240730874079/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
